PFE

Pfizer Inc. Q2 2008 10-Q Summary

Business Context and Reporting Period

This filing is a Quarterly Report on Form 10-Q for Pfizer Inc. for the three and six months ended June 29, 2008. Pfizer is a global research-based company engaged in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals. The company operates primarily through two segments: Pharmaceutical and Animal Health.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Q2 2008 revenues increased 9% year-over-year, driven by a 9% increase in Pharmaceutical revenues and a 13% increase in Animal Health revenues. International revenues grew 18%, offsetting a 2% decline in U.S. revenues.
• Profitability Surge: Net income increased 119% in Q2 2008 compared to Q2 2007. This was primarily due to a significantly lower effective tax rate (0.9% vs 16.8%) resulting from $305 million in foreign tax settlement benefits and a $426 million tax benefit from the sale of Esperion Therapeutics.
• Cost Reductions: Restructuring charges and acquisition-related costs decreased 46% in Q2 2008 ($569 million) compared to Q2 2007 ($1,051 million), reflecting progress in cost-reduction initiatives.
• Acquisition Charges: Acquisition-related in-process research and development (IPR&D) charges were $156 million in Q2 2008 (related to Encysive and Serenex acquisitions) compared to zero in Q2 2007.
• Product Mix Impact: Revenues were negatively impacted by the loss of U.S. exclusivity for Zyrtec/Zyrtec D (Jan 2008) and Camptosar (Feb 2008), partially offset by strong growth in Lyrica (+52%), Sutent (+45%), and Chantix/Champix (+3% Q2, +33% 6mo).

Guidance, Outlook, and Risks

• 2008 Guidance: Pfizer forecasts full-year 2008 revenues of $47.0 billion to $49.0 billion. Reported diluted EPS is expected to be $1.73 to $1.88, while Adjusted diluted EPS is expected to be $2.35 to $2.45. Operating cash flow is projected at $17 billion to $18 billion.
• Cost Reduction Target: Management expects to achieve a net reduction of the pre-tax total expense component of Adjusted income of at least $1.5 billion to $2.0 billion by the end of 2008 (constant currency basis vs. 2006). As of June 29, 2008, $1.2 billion of this target had been achieved.
• Key Risks:
  • Patent Expirations: Continued revenue pressure from generic competition following the loss of exclusivity for major products like Lipitor (competitive pressures), Norvasc, Zyrtec, and Camptosar.
  • Legal Proceedings: Ongoing patent litigation regarding Lipitor and Caduet (settled with Ranbaxy for 2011 entry in U.S., but litigation continues in some European countries), Celebrex, and Norvasc. Product liability litigation regarding Rezulin was dismissed with a favorable settlement.
  • Regulatory Environment: Risks related to FDA approvals for pipeline products (e.g., lasofoxifene, Thelin) and potential labeling changes for products like Chantix and Lyrica.
  • Foreign Exchange: While favorable for revenue, currency fluctuations have an adverse impact on reported expenses.

Investor Verification Checklist

• Tax Benefit Sustainability: Verify the non-recurring nature of the $731 million in tax benefits ($305M settlement + $426M Esperion sale) that drove the Q2 profit surge.
• Lipitor Competitive Landscape: Monitor the impact of generic simvastatin and pravastatin on Lipitor sales, which remains the company's top revenue generator despite a 1% decline in U.S. sales for the first six months.
• Cost-Reduction Execution: Confirm the realization of the remaining $0.3 billion to $0.8 billion of the cost-reduction target in Q4 2008.
• Patent Litigation Outcomes: Track the status of ongoing Lipitor and Caduet patent challenges in Europe and the U.S. (Teva challenge) which could impact future revenue streams.
• Acquisition Integration: Assess the integration and pipeline potential of recent acquisitions (Encysive, Serenex, Coley, CovX) given the $554 million in IPR&D charges recorded in the first half of 2008.